Bone Marrow Failure Syndrome (BMFS) Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
Conditions: Primary Immune Deficiency Disorders; Hemophagocytic Lymphohistiocytosis; Inherited Bone Marrow Failure Syndrome; Hemoglobinopathies; Metabolic DisordersIntervention: Biological: BPX-501 and AP1903Sponsor: Bellicum PharmaceuticalsNot yet recruiting - verified September 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2014 Category: Research Source Type: clinical trials

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
Conditions: Primary Immune Deficiency Disorders; Hemophagocytic Lymphohistiocytosis; Inherited Bone Marrow Failure Syndrome; Hemoglobinopathies; Metabolic DisordersIntervention: Biological: BPX-501 and AP1903Sponsor: Bellicum PharmaceuticalsRecruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2014 Category: Research Source Type: clinical trials

Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Conditions: Multiple Myeloma; Bone Marrow Failure Syndromes; Hemoglobinopathies; AML; ALL; Myeloid Leukemia, Chronic; NHL; HL; MDS; Amyloidosis; MyelofibrosisInterventions: Drug: Tacrolimus; Drug: Anti-thymocyte globulin; Procedure: Kidney transplant; Drug: Bone marrow transplant from a related donor; Radiation: Total body irradiation 400 centigray (200 cGy X 2)Sponsor: Massachusetts General HospitalRecruiting - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 30, 2014 Category: Research Source Type: clinical trials

Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Conditions: Primary Immunodeficiency Syndromes; Congenital Bone Marrow Failure Syndromes; Inherited Metabolic Disorders (IMD); Hereditary Anemias; Patients With Sickle Disease Presenting Specific SymptomsInterventions: Drug: Hydroxyurea; Drug: Alemtuzumab; Drug: Fludarabine; Drug: Melphalan; Drug: ThiotepaSponsor: University of PittsburghRecruiting - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2013 Category: Research Source Type: clinical trials